contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


peptonic-medical-ab-peptonic-medical-ab-styrelsen-utser-daniel-rudeklint-till-interim-vd

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Peptonic Medical is a biomedical company that conducts research and development of pharmaceuticals and medical devices in the field of women's health. The company's vision is to offer treatments for women-specific diseases and medical conditions. For example, hormone-free products are being developed for the treatment of vaginal atrophy and vaginal dryness. Peptonic Medical has its headquarters in Bromma.

STOCKHOLM (Nyhetsbyrån Direkt) Medtech company Peptonic Medical has decided to file an application for corporate restructuring. “The decision is an extraordinary measure due to a long-term strained liquidity situation and aims to create conditions for a stable and profitable business. External consultants have evaluated the situation and assessed that Peptonic has good chances of being granted reconstruction,” the company writes in a press release. Via Google Translate: STOCKHOLM (Nyhetsbyrån Direkt) Lääketieteen teknologiayritys Peptonic Medical on päättänyt jättää hakemuksen yrityssaneeraukseen. “Päätös on poikkeuksellinen toimenpide, joka johtuu pitkäaikaisen paineen aiheuttamasta likviditeettitilanteesta ja sen tavoitteena on luoda edellytykset vakaalle ja kannattavalle toiminnalle. Ulkopuoliset konsultit ovat arvioineet tilanteen ja arvioineet, että Peptonicilla on hyvät mahdollisuudet saada uudelleenjärjestely”, yhtiö kirjoittaa tiedotteessa.

I follow it every now and then. I own a small position - and based on the share price development and having read the last couple of interim reports, I don’t dare to put more money into this. Reason: In 2022, they said the company would break even in 2024.  Since then, there have been repeated share issues, and now the story is that cash flow would be positive in the second half of 2025. In 2021, they acquired a company called Common Sense from Israel. A moment ago, they announced its shutdown and gave cost reduction as the reason? Does anyone remember/can find the purchase price? It seems, however, that a loss was incurred. And are those gels applied to the labia and vaginal area really that special after all?  The company hyped up a lot in 2023 how they are expanding distribution to Central and South America, but this year no hype has been heard. I wonder why? Eh. Good luck to everyone who has put their money into this. I’m just waiting to sell some other stock so I can get out of this tracking position. I no longer believe in this company’s future. I’ll look into it again when they achieve a profitable result for at least two consecutive quarters.

I quickly found out that a new rights issue is on the way. For every current share, you would receive 4 new shares. And the price, if you then buy/exercise them, would be 0.01 SEK/share.

Is anyone still following this? I wonder what’s happening there since I don’t understand the terminology. Quite a brutal drop today.

Peptonic Medical AB (publ) (“Peptonic”) announced today that the company has agreed with the world’s largest retail chain Walmart to begin selling Peptonic’s self-test for bacterial vaginosis. The US is an important market. It is very gratifying that Walmart has decided to sell our patented self-test for bacterial vaginosis," says Erik Sundquist, CEO of Peptonic Medical. “Increasing the distribution of our products is an important part of our strategy, which makes this agreement with the world’s largest retail chain Walmart extra positive and also shows that the need for our products is great. It paves the way for rapid growth in what is already our largest market today,” says Erik Sundquist. The distribution agreement with Walmart, which has approximately 10,500 stores worldwide, of which just under 5,000 are in the United States, primarily applies to Peptonic’s patented self-test for diagnosing bacterial vaginosis. The test will be sold under Walmart’s own brand. What makes the test unique is the combination of high precision and immediate results. The distribution agreement applies to the United States and Walmart is now conducting an overview of stores currently for distribution. In Peptonic’s American organization, since the beginning of summer 2023, Angella Garcia is responsible for retail chains. Angella has extensive experience in sales to these channels in the US, but also in medtech. Through the agreement with Walmart, there is also a dialogue about the distribution of a further selection of Peptonic’s current and future products. Pharmiva’s product Vernivia will be an excellent and unique treatment solution for the self-test for bacterial vaginosis. Peptonic expects the agreement to have a positive impact on the company’s sales from 2024. Jaa että uusi jakelusopimus. Kuulostaa hyvältä, mutta menevätkö tuotteet kaupaksi loppuasiakkaille?  Entä paljonko tuotteille saadaan katetta? En oikein pääse kärrylle kokonaisuudesta.  Siemens myy Pepin tuotteita, Walmart myy samoja tuotteita. Kilpailevatko Pepin tuotteet toisiaan vastaan kahden eri jakelijan välillä?  Entä miten pakkaa sekottaa fuusioituminen Pharmivan kanssa? Toteutuuko voitollinen tulos vuonna 2024? Pohdittavaa riittää. Lisäsin hieman Pepiä salkkuuni kruunun edullisen kurssin vuoksi.

Peptonic Medical AB (publ) today announces that the Stockholm District Court has rejected the Swedish Economic Crime Authority’s (EBM) claim for a corporate fine for Peptonic of SEK 500,000. The judgment relates to the investigation of serious insider crime that Peptonic previously informed about and which are related to measures taken by the company within the framework of a financing arrangement between the company and a financial actor in the spring of 2019. At the beginning of 2022, Peptonic was informed that EBM intended to claim a corporate fine for Peptonic of SEK 500,000 due to the investigation. EBM reiterated its claim in September 2022 in connection with the former chairman, CEO and CFO of the company being charged with serious insider crime. According to the judgment from the District Court, the accused persons and the company are now acquitted on all counts. Peptonic reserved an amount corresponding to the corporate fine in its third quarter 2022 results. Peptonic intends to decide to dissolve the reserve in connection with results for the second quarter of 2023. Google translate vomit  Peptonic Medical AB (publ) announced today that the Stockholm District Court has rejected the Swedish Economic Crime Authority’s (EBM) demand for a corporate fine of SEK 500,000 for Peptonic. The judgment concerns the investigation into serious insider crime previously reported by Peptonic, which relates to measures taken by the company in the spring of 2019 within the framework of a financing arrangement between the company and a financial actor. At the beginning of 2022, Peptonic was informed that EBM intended to demand a SEK 500,000 corporate fine for Peptonic due to the investigation. EBM reiterated its demand in September 2022 when the company’s former chairman, CEO, and CFO were charged with serious insider crime. According to the District Court’s judgment, the accused and the company have now been acquitted of all charges. Peptonic reserved an amount corresponding to the corporate fine in its third-quarter 2022 results. Peptonic intends to decide on the reversal of the reserve in connection with the results for the second quarter of 2023. So the charges have been dismissed. I wonder if they will take these employees back now?

2023-06-15 13:00:00 - Cision International  PEPTONIC Medical AB : Peptonic and Pharmiva sign letter of intent to merge and create a leading intimate women’s health company  The FemTech companies PEPTONIC medical AB (“Peptonic”), listed on Spotlight Stock Market, and Pharmiva AB (publ) (“Pharmiva”), listed on Nasdaq First North  Growth Market, have signed a letter of intent with the intention of combining the companies through a planned merger (the “Letter of Intent”). The Boards of Directors of Peptonic and Pharmiva (together the “Companies”) have signed a letter of intent to clarify the Companies intention regarding a merger  of Peptonic and Pharmiva. The joining of the two companies is planned to be completed through a merger under Swedish company law (the “Merger”). The completion  of the Merger is conditional upon, inter alia, that the Boards of Directors of each company resolve to complete the Merger and that the Merger is approved by an  extraordinary general meeting in Pharmiva. The final decision on the merger will be made after union negotiations have been completed. According to the Letter of Intent, the ownership in the joint venture shall, indicatively, correspond to the following: (a)    Peptonic’s holding is intended to amount to eighty-five (85) percent of the number of shares in New Peptonic. (b)    Pharmiva’s holding is intended to amount to fifteen (15) percent of the number of shares in New Peptonic. In order to carry out the distribution as above, the Company’s intention is, indicatively, that shareholders in Pharmiva shall receive [twelve (12)] shares in  Peptonic for each one (1) share owned in Pharmiva in the form of merger consideration. However, the final merger consideration will be determined after the  Companies have prepared and adopted a joint merger plan for the Merger. The planned Merger in brief · The merger is intended to be carried out by Peptonic absorbing Pharmiva, which will subsequently be dissolved.  · The proposed merger requires, among other things, that the Companies’ boards of directors resolve to adopt a joint merger plan and that the Merger is  approved by an extraordinary general meeting of Pharmiva. No final decision on the merger will be made until the union negotiations have been completed.  · Declarations have been made with shareholders of Pharmiva regarding the contemplated Merger, and shareholders representing more than 37 percent of the  shares in Pharmiva have undertaken or given their intention to vote in favour of the proposed Merger at an extraordinary general meeting, provided that the  other conditions for completion of the Merger are fulfilled.  · The completion of the Merger will not be dependent on any financing as the Merger Consideration will consist exclusively of new shares in Peptonic.  · More information about the Merger and the merger plan is expected to be published around the week 27 2023  · A merger document is expected to be published around week 29 2023. Allekirjoittaneelle tämä tieto tuli puskista. Pharmivaa en myöskään tiedä entuudestaan. Seuraan mielenkiinnolla, mitä tämä fuusio tuo tullessaan.

Peptonic Medical

Peptonic Medical AB (publ) ("Peptonic") tillkännager utnämningen av Daniel Rudeklint till interim VD med omedelbar verkan. Daniel Rudeklint ersätter Anna Linton som VD.Daniel Rudeklint sitter...

<div class="abstract">Peptonic Medical AB (publ) ("Peptonic") tillkännager utnämningen av Daniel Rudeklint till interim VD med omedelbar verkan. Daniel Rudeklint ersätter Anna Linton som VD.</div>Daniel Rudeklint sitter i Peptonics styrelse sedan januari 2023 och har en stark finansiell bakgrund, mycket god insikt i bolaget samt en gedigen erfarenhet av att leda organisationer. Arbetet med att rekrytera en ny permanent VD pågår."På styrelsens vägnar tackar jag Anna för det arbete hon utfört under det senaste året som VD för Peptonic och hur hon visat engagemang och lojalitet mot företaget", säger styrelseordförande Anders Blom.&nbsp;För ytterligare information kontakta: Daniel Rudeklint, tf VD Peptonic Medical AB Email:&nbsp;<a href="mailto:daniel.rudeklint@peptonicmedical.se">daniel.rudeklint@peptonicmedical.se</a> Telefon:&nbsp; +46 73&nbsp;158 02 73&nbsp;Kort om Peptonic Medical AB&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Peptonic Medical AB (publ) är ett svenskt medicintekniskt bolag som utvecklar och säljer kliniskt bevisade egenvårdsprodukter inom intim kvinnohälsa. Under varumärkena VagiVital och Vernivia erbjuder Bolaget en receptfri portfölj av effektiva och skonsamma produkter som hjälper kvinnor att förstå, behandla och förebygga vanliga medicinska tillstånd i underlivet. Peptonics tillväxtstrategi bygger på geografisk expansion, särskilt i USA och Europa, och på att kontinuerligt stärka produktportföljen genom egen produktutveckling och strategiska förvärv. Bolaget har sitt huvudkontor i Stockholm, Sverige, och dotterbolagen Peptonic Medical Inc. och Common Sense Marketing Inc. i USA. Peptonic Medical grundades 2009 och är sedan 2014 noterat på Spotlight Stock Market. <div></div>